ABBV vs DXCM
By Alex · Tickerpine
AbbVie Inc. vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | DXCM |
|---|---|---|
| Price | $295.03 | $83.33 |
| Market cap | $521.50B | $31.08B |
| P/E ratio | 50.7 | 32.8 |
| ROE | — | 37.67% |
| Profit margin | 15.67% | 19.42% |
| Revenue growth | 10.30% | 11.20% |
| Dividend yield | 2.35% | 0.00% |
| Beta | 0.19 | 1.44 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs DXCM in plain English
- ABBV is the bigger company — about 16.8× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 32.8 vs 50.7).
- DXCM is growing revenue faster (11% vs 10%).
- ABBV pays a dividend (2.35%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.